Gilgamesh Pharmaceuticals Raises $27M In Series A With Prime Movers Lab
Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round led by Prime Movers Lab.
